#United States #Abbott #Medtronic #Galway #MiniMed Go™

Medtronic Innovations: MiniMed Go™ Smart MDI System

In a groundbreaking development for diabetes management, Medtronic Diabetes has recently announced the FDA's 510(k) clearance for its MiniMed Go™ Smart Multiple Daily Injection (MDI) system. This innovative solution features the integration of the InPen™ smart insulin pen and Abbott's Instinct sensor, all linked through the MiniMed Go™ application. This coupling provides users with personalized, real-time insights and actionable instructions that significantly improve diabetes care for individuals requiring insulin injections.

Understanding the MiniMed Go™ System

The MiniMed Go™ system represents a revolution in diabetes technology. It allows users aged seven and older, as well as children from two to six years under adult supervision, to access a sophisticated system that centralizes their insulin dosing and glucose data within a single application. The convenience of this system aids patients in managing their diabetes more effectively and with greater peace of mind.

The features of the MiniMed Go™ system include:

• - Missed dose alerts to help prevent accidental missed doses that can cause glucose levels to spike or drop dangerously.
• - An intuitive dose calculator to simplify the often-daunting process of determining the correct insulin dose based on carbohydrate intake.
• - Action-oriented guidance for those who might miss or miscalculate an injection, ultimately promoting better adherence to their insulin therapy.
• - Integration with CareLink™ software for enhanced collaboration between users and healthcare providers, facilitating a seamless exchange of health information.

Addressing a Critical Need

Globally, over 15 million individuals rely on multiple daily insulin injections for diabetes management. These patients often face monumental challenges during mealtimes, requiring them to meticulously calculate their carbohydrate intake and adjust their insulin accordingly. This ongoing stress can lead to what is known as diabetes distress, a condition that can significantly impede effective diabetes management.

Research indicates that even missing just a couple of doses weekly can lead to undesirable increases in HbA1c levels, elevating the risk for both immediate and long-term complications. Therefore, the ability to receive timely notifications and advice from a tool like the MiniMed Go™ may be transformative, potentially leading to improved glycemic outcomes.

Data from the previous Medtronic Smart MDI system users reflected substantial improvements in patient health metrics, notably an increase in Time in Range (TIR) from 55.7% to a remarkable 67.2% when they acted on more than 75% of missed dose alerts. This statistic showcases the effectiveness of immediate feedback in fostering better diabetes management and health results.

Empowering Patients with Technology

Commenting on the launch of the MiniMed Go™, Que Dallara, the Executive Vice President and President of Medtronic Diabetes, expressed that the system aims to lift the burden of complex insulin management from those relying on injections. By integrating smart technology into an easy-to-use application, the MiniMed Go™ empowers individuals to manage their diabetes with confidence.

Dallara stated, “For too long, people using injections have carried the weight of diabetes management without access to the algorithms that make automated insulin delivery systems so powerful.” He emphasized that the MiniMed Go™ system brings the advanced features of automated insulin delivery to individuals who prefer using an insulin pen.

Launch Plans and Future Outlook

Medtronic has plans to launch the MiniMed Go™ system commercially in the United States this upcoming spring. This initiative marks another step forward in the company's commitment to transforming diabetes management through user-friendly technology that provides reliable assistance in navigating daily injections.

For more information about the MiniMed Go™, interested individuals can visit Medtronic's website, which outlines details about how this system is designed to revolutionize diabetes care.

Conclusion

The MiniMed Go™ Smart MDI system heralds a new era in diabetes management by merging essential technologies that cater specifically to insulin-requiring individuals. By addressing significant unmet needs in diabetes care, Medtronic not only enhances the quality of life for its users but also places vital tools for health improvement directly into their hands, making daily management less burdensome and more effective.